Insulet has launched the Omnipod 5 automated insulin delivery app for iPhone in the US. The app obviates the need for ...

Insulet Corporation (NASDAQ: PODD) reported Q3 sales of $432.7 million, up 27.0%, or 25.1% in constant currency, beating the consensus of $414.383 million. Total Omnipod revenue of $422 million ...

Insulet (NASDAQ:PODD) announced Friday that its tubeless insulin delivery system, Omnipod 5, performed better than conventional insulin pumps in a clinical trial for patients with type 1 diabetes.

Insulet (Nasdaq:PODD) today announced the full market release of the Omnipod 5 automated insulin delivery app for iPhone in the U.S.

(Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the full market release of the Omnipod 5 App for iPhone® in ...

Insulet (Nasdaq:PODD) today announced its plans to recognize National Diabetes Awareness Month and World Diabetes Day.

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced plans to recognize National ...

Insulet's Omnipod The deal has been axed a few weeks after a federal judge in the US blocked EOFlow from selling its insulin patch pump in a lawsuit brought by Insulet, which sells a rival product.

ACTON, Mass.–(BUSINESS WIRE)–Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced ...

Insulet Corp ... including the OmniPod System, as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and ...